New cholesterol methods needed in wake of failed drugs: researchers
London
NEW ways of controlling cholesterol, including possibly directly injecting "good" HDL cholesterol into patients, need to be studied following the failure of promising treatments from Eli Lilly, Pfizer Inc and Roche Holding AG, according to top heart researchers.
Lilly in October halted a 12,000-patient study of its experimental drug evacetrapib, an oral medication that in smaller earlier studies slashed "bad" LDL cholesterol and doubled levels of HDL.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Puma returns to sales growth in Americas despite ‘volatile’ market
Nanjing Xinjiekou Department Store announces May 23 EGM; Cordlife seeking legal advice
Olam tops Louis Dreyfus’ offer for Australia’s Namoi Cotton as takeover battle heats up
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
‘Limits’ to MOH intervention for Cordlife customer refunds, compensation: Janil
UG Healthcare fully acquires German associate company for 16.9 million euros